Brief: Dyne Therapeutics Announces U.S. FDA Clearance Of Investigational New Drug (Ind) Application For Dyne-302 In Facioscapulohumeral Muscular Dystrophy (Fshd)
28/07/2026 12:50
BRIEF-Dyne Therapeutics Announces U.S. FDA Clearance Of Investigational New Drug (Ind) Application For Dyne-302 In Facioscapulohumeral Muscular Dystrophy (Fshd) July 28 (Reuters) - Dyne Therapeutics, Inc DYN.O:
DYNE THERAPEUTICS ANNOUNCES U.S. FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR DYNE-302 IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
DYNE THERAPEUTICS, - TO CONDUCT PHASE 1 PLACEBO-CONTROLLED TRIAL FOR DYNE-302 IN FSHD
Source text: ID:nGNXR4Ym7
Further company coverage: DYN.O
((Reuters.Briefs@thomsonreuters.com;))